NF-κB signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links

被引:79
作者
Pateras, Ioannis [1 ,2 ]
Giaginis, Constantinos [1 ,3 ]
Tsigris, Christos [2 ]
Patsouris, Efstratios [1 ]
Theocharis, Stamatios [1 ]
机构
[1] Univ Athens, Dept Pathol 1, Sch Med, Athens 11528, Greece
[2] Univ Athens, Laikon Gen Hosp, Sch Med, Dept Surg 1, Athens 11528, Greece
[3] Univ Aegean, Dept Food Sci & Nutr, Myrina 81400, Lemnos, Greece
关键词
atherosclerosis pathophysiology; carotid plague evolution stages; inflammation; NF-kappa B inhibitors/enhancers; NF-kappa B signaling; SMOOTH-MUSCLE-CELLS; ADVANCED GLYCATION ENDPRODUCTS; HUMAN ATHEROSCLEROTIC LESIONS; DEPENDENT PLAQUE STABILIZATION; CORONARY-ARTERY-DISEASE; LOW-DENSITY-LIPOPROTEIN; C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE; SUBCLINICAL HYPOTHYROIDISM; CAROTID ATHEROSCLEROSIS;
D O I
10.1517/14728222.2014.938051
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: NF-kappa B is a protein complex acting as a primary transcription factor and fast messenger to harmful cellular stimuli, including inflammation. Carotid atherosclerosis is an inflammatory process leading to atheroma formation and ultimately complicating the patient's condition. This review aims to critically summarize the role of NF-kappa B in atheroma formation and evolution, also highlighting its potential therapeutic utility. Areas covered: This literature review presents the most recent data in terms of NF-kappa B, atherosclerosis and implicating factors, with special focus on the carotid artery setting. Results are categorized according to atheroma stage and are discussed for each one respectively, forming an NF-kappa B mediated atherosclerosis evolvement model per stage. Targeting NF-kappa B by inhibitors or enhancers and their potential effectiveness are also discussed. Expert opinion: The current data suggest that NF-kappa B plays a critical role in all stages of plaque evolution toward complexity, implicating genes, membrane and cellular proteins, polypeptides, chemokines and hormones. It also seems capable of assisting several pharmaceutical agents, unfolding either directly or indirectly their anti-inflammatory/anti-atherogenic properties. Targeting NF-kappa B signaling by specific inhibitors or enhancers may provide new therapeutic strategies against atherogenic inflammatory process.
引用
收藏
页码:1089 / 1101
页数:13
相关论文
共 99 条
[1]   NF-κB activation [J].
Abraham, E .
CRITICAL CARE MEDICINE, 2000, 28 (04) :N100-N104
[2]   Identification of scavenger receptor SR-BI as a high density lipoprotein receptor [J].
Acton, S ;
Rigotti, A ;
Landschulz, KT ;
Xu, SZ ;
Hobbs, HH ;
Krieger, M .
SCIENCE, 1996, 271 (5248) :518-520
[3]   Aspirin [J].
Awtry, EH ;
Loscalzo, J .
CIRCULATION, 2000, 101 (10) :1206-1218
[4]   The NF-kappa B and I kappa B proteins: New discoveries and insights [J].
Baldwin, AS .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :649-683
[5]   Chemokine regulation of atherosclerosis [J].
Barlic, Jana ;
Murphy, Philip M. .
JOURNAL OF LEUKOCYTE BIOLOGY, 2007, 82 (02) :226-236
[6]   A fourth IκB protein within the NF-κB signaling module [J].
Basak, Soumen ;
Kim, Hana ;
Kearns, Jeffrey D. ;
Tergaonkar, Vinay ;
O'Dea, Ellen ;
Werner, Shannon L. ;
Benedict, Chris A. ;
Ware, Carl F. ;
Ghosh, Gourisankar ;
Verma, Inder M. ;
Hoffmann, Alexander .
CELL, 2007, 128 (02) :369-381
[7]   Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications [J].
Basta, Giuseppina .
ATHEROSCLEROSIS, 2008, 196 (01) :9-21
[8]   Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis [J].
Boring, L ;
Gosling, J ;
Cleary, M ;
Charo, IF .
NATURE, 1998, 394 (6696) :894-897
[9]   Use of ramipril in preventing stroke: double blind randomised trial [J].
Bosch, J ;
Yusuf, S ;
Pogue, J ;
Sleight, P ;
Lonn, E ;
Rangoonwala, B ;
Davies, R ;
Ostergren, J ;
Probstfield, J .
BMJ-BRITISH MEDICAL JOURNAL, 2002, 324 (7339) :699-702
[10]   The NF-κB regulatory network [J].
Brasier, Allan R. .
CARDIOVASCULAR TOXICOLOGY, 2006, 6 (02) :111-130